Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, Arad M.
Arow M, et al. Among authors: abraham ng.
Cardiovasc Diabetol. 2020 Jan 10;19(1):7. doi: 10.1186/s12933-019-0980-4.
Cardiovasc Diabetol. 2020.
PMID: 31924211
Free PMC article.